Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans

Special Operations Forces Veterans (SOFV) experience intense and repeated combat exposures that place them at elevated risk for mental health problems, including post-traumatic stress symptoms and high rates of alcohol misuse. Earlier research and public health reporting indicate substantial prevalence of alcohol use disorder and heavy episodic drinking among US Veterans, and comorbidity between PTSD and alcohol misuse is common; the self-medication hypothesis has been invoked to explain part of this relationship. Approved pharmacologic treatments for alcohol use disorder (disulfiram, naltrexone, acamprosate) have limited evidence of benefit in Veteran samples, and effective, acceptable interventions for comorbid PTSD and alcohol misuse remain an important unmet need in this population. Mangini and colleagues set out to explore whether participation in a specific clinical programme involving sequential administration of ibogaine and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) was associated with changes in alcohol consumption and PTSD symptoms among SOFV. The study used a retrospective, anonymous internet survey asking participants to report alcohol use, PTSD symptoms, and psychological flexibility for the 30 days before and 30 days after the psychedelic treatment; the primary aim was to assess associations between the psychedelic intervention and reductions in alcohol use and PTSD symptoms in this high‑risk clinical sample.

This analysis used data drawn from a previously published, anonymous internet-based survey of SOFV who attended an ibogaine and 5-MeO-DMT clinical programme in Mexico between 2017 and 2019. Recruitment occurred April–September 2019: emails were sent to 65 eligible patients (those who had completed the clinic programme), weekly for four weeks, with a link to a secure anonymous survey. Participation required informed consent; the study was approved by an institutional review board (Solutions IRB) and no compensation was provided. Fifty-one SOFV (78% of the 65 treated) completed the original survey; the present analyses were restricted to the 27 respondents who retrospectively screened positive for alcohol misuse (AUDIT-C ≥ 4) in the month prior to treatment. The clinical programme took place over three days in a residential setting. On day one a therapist-led group session reviewed potential psychedelic effects, mindfulness strategies, and treatment goals; toxicology and breathalyser screens ensured no contraindicated substances were present. Ibogaine hydrochloride (single oral dose at 10 mg kg, 99% purity) was administered with continuous medical monitoring including cardiac surveillance and intravenous fluids. Day two focused on journalling and one-on-one or optional group psychological support. On day three participants prepared for and received inhaled 5-MeO-DMT across multiple escalating doses (reported as 5 mg, 15 mg and 30 mg, totalling approximately 50 mg), with additional 30 mg doses and, if necessary, further dosing up to 45 mg for those who did not attain an observed altered state; integration support followed the acute effects. Outcomes were assessed retrospectively for the 30 days before and 30 days after treatment. Alcohol use was measured with the AUDIT-C (three-item Alcohol Use Disorders Identification Test—Consumption) with scores ≥ 4 indicating potential misuse. PTSD symptoms were measured with the PCL-5 (the 21-item PTSD Checklist for DSM-5). Psychological flexibility was measured with the AAQ-II (Acceptance and Action Questionnaire II); lower scores indicate greater psychological flexibility. Change scores were calculated by subtracting the post-treatment mean from the pre-treatment mean for each measure. The extracted text reports paired comparisons with p-values and Cohen's d effect sizes, and Pearson correlations were used to examine associations between changes in psychological flexibility and changes in alcohol use and PTSD symptoms. The extraction does not clearly specify the exact statistical tests used for the group comparisons beyond reporting p-values, effect sizes, and Pearson correlation coefficients.

The analytic sample consisted of 27 SOFV who retrospectively screened positive for alcohol misuse in the month before treatment. Participants were predominantly male (96%), primarily Caucasian/White (96%), and middle-aged (mean age 40, SD 5.5). Educational and military characteristics: 48% reported a bachelor's degree, 67% were married and living with their spouse, 74% had served in the Navy, and 89% began service in September 2001 or later; most (93%) had served in Operations Enduring Freedom/Iraqi Freedom/New Dawn. Number of deployments ranged from 1 to 18. Pre-treatment alcohol-risk categories were: 30% moderate risk (AUDIT-C 4–5; N = 8), 26% high risk (AUDIT-C 6–7; N = 7), and 44% severe risk (AUDIT-C 8–12; N = 12). In the 30 days after treatment, 33% (N = 9) reported complete abstinence (AUDIT-C = 0), 52% (N = 14) reported non‑risky/low-risk drinking (AUDIT-C 1–3), and 4% (N = 1) remained at severe-risk levels. Statistically significant and large retrospective within-subject changes were reported across outcomes. Alcohol use decreased (P < 0.001; Cohen's d reported as -2.4), PTSD symptoms decreased (P < 0.001; d = -2.8), and psychological flexibility improved (P < 0.001; d = -1.8). The AAQ-II scores decreased post-treatment, and the authors note that decreasing AAQ-II scores correspond to greater psychological flexibility. Pearson correlations indicated that increases in psychological flexibility were moderately associated with reductions in alcohol use (r = 0.38, P = 0.049) and strongly associated with reductions in PTSD symptoms (r = 0.90, P < 0.001). The extracted text does not provide confidence intervals or detailed model diagnostics.

Mangini and colleagues interpret their findings as showing that participation in a short, residential programme involving sequential administration of ibogaine and 5-MeO-DMT was associated with large, rapid, retrospectively reported reductions in alcohol use and PTSD symptoms among a clinical sample of SOFV. The observed associations are presented as consistent with prior clinical and preclinical evidence suggesting psychedelics can reduce PTSD symptoms (for example, work with MDMA) and that ibogaine and related compounds may reduce alcohol consumption in animal models and in case reports. The authors highlight psychological flexibility as a potential mediator or mechanism, noting strong correlations between improved psychological flexibility (lower AAQ-II scores) and reductions in both alcohol use and PTSD symptoms; they reference the broader literature in which psychological inflexibility is implicated in PTSD and alcohol-use disorders and where therapies that increase flexibility (such as Acceptance and Commitment Therapy) have clinical benefit. Neurobiological mechanisms are also discussed: ibogaine has been reported in animal studies to induce glial-derived neurotrophic factor (GDNF) expression in the ventral tegmental area (VTA) and reduce ethanol self-administration, while 5-MeO-DMT's agonism at the 5-HT2A receptor may reduce mesolimbic dopamine signalling and thus impair reward-related maintenance of alcohol use. For PTSD symptoms, the authors note theories involving memory reconsolidation, fear extinction, and amygdala/hippocampal modulation by psychedelics. Several important limitations are acknowledged. The study used a cross-sectional, retrospective self-report design with potential selection bias because participants self‑selected into treatment and into responding to the survey; those with neutral or negative outcomes may be underrepresented. Recall bias could have inflated perceived improvements, and the lack of randomisation, blinding, and any control group—constraints the authors attribute in part to regulatory scheduling of the substances—precludes causal inference. Generalisability is limited by the small, demographically homogeneous sample (predominantly middle-aged White men who are SOF Veterans). The sequential administration of two different agents in a single programme complicates attribution of effects to one substance versus the other. The authors also note they did not assess longer-term durability of changes. In light of these constraints, the study team calls for rigorous, longitudinal, controlled studies using laboratory drug administration, clinician-rated outcomes, and designs that can disentangle effects of ibogaine and 5-MeO-DMT. They emphasise the need to evaluate clinical safety and the persistence of benefits over time before concluding whether psychedelic-assisted interventions could be effective treatment options for comorbid alcohol misuse and PTSD in Veteran populations.